Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Apatinib in Recurrent Ovarian Cancer or TNBC
NCT03075462Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in ovarian cancer and triple-negative breast cancer (TNBC), sponsored by Hengrui. Primary endpoint: Type and incidence of adverse events. Started Mar 2017; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03075462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075462.